TKTL1 and kidney cancer: Our work implies that TKTL1 may be a promising prognostic biomarker for KIRC patients that respond to anti-PD-1 therapy, providing insight into the possible role of TKTL1 in tumor immunology and its application as a prognostic biomarker and novel therapeutic target for kidney cancer.